Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice

Keyphrases

• Anti-metastasis 33%
• Anti-VEGF Antibody 33%
• Antiangiogenic Agents 100%
• Antiangiogenic Therapy 33%
• Antitumor Effect 33%
• Attenuation 33%
• Cell Proliferation 33%
• Clinical Benefit 33%
• Colorectal Liver Metastases 100%
• Curative Strategies 33%
• Drug Combination 100%
• Functional Magnetic Resonance Imaging 33%
• Hemodynamic Imaging 33%
• Hepatic Perfusion 100%
• Hypercapnia 33%
• Hyperoxia 33%
• Improved Efficacy 100%
• In Cancer 33%
• Initial Treatment 33%
• Liver Metastasis 66%
• Metastasis 33%
• Mouse Model 33%
• Mouse Survival 33%
• MRI Monitoring 100%
• Nitric Oxide 33%
• Nitric Oxide Inhibitor 66%
• Patients with Colorectal Cancer 33%
• Perfusion Density 33%
• Poor Prognosis 33%
• Proliferation Apoptosis 33%
• Rapamycin 33%
• Serum Levels 33%
• Therapeutic Effect 33%
• Therapeutic Potential 66%
• Treatment Efficacy 33%
• Treatment Phase 33%
• Tumor Progression 33%
• Vascular Changes 33%
• Vessel Density 66%

Pharmacology, Toxicology and Pharmaceutical Science

• Angiogenesis Inhibitor 100%
• Antiangiogenic Therapy 25%
• Colorectal Carcinoma 100%
• Combination Drug 100%
• Hypercapnia 25%
• Liver Metastasis 100%
• Malignant Neoplasm 50%
• Mouse Model 25%
• Neoplasm 25%
• Nitric Oxide 75%
• Rapamycin 25%
• Therapeutic Effect 25%
• Tumor Growth 25%
• Vasculotropin Antibody 25%